A Phase 3 Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Previous TKIs Therapy Including Imatinib

Trial Profile

A Phase 3 Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Previous TKIs Therapy Including Imatinib

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Radotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Il-Yang
  • Most Recent Events

    • 13 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top